Search

Displaying results 5321 - 5330 of 10000 in total
  1. Drug

    Pardoprunox

    go.drugbank.com/drugs/DB12061
    Investigational

    Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease. … Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.

  2. Drug

    Abexinostat

    go.drugbank.com/drugs/DB12565
    Investigational

    Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. … It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.

  3. Drug

    RTN-001

    go.drugbank.com/drugs/DB05615
    Investigational

    SLx-2101 is an oral, long-acting PDE5 inhibitor developed by Surface Logix Inc. to treat Hypertension.

  4. Drug

    ATL-104

    go.drugbank.com/drugs/DB05670
    Investigational

    ATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.

  5. Drug

    R-851

    go.drugbank.com/drugs/DB05747
    Experimental

    R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and tumor cells. … It is expected to be topical treatment for cervical displasia and cervical high-risk human papillomavirus (HPV), the sexually transmitted virus that causes most cases of cervical cancer.

  6. Drug

    Piretanide

    go.drugbank.com/drugs/DB02925
    Approved

    an aromatic nucleus in the presence of other aromatically bonded functional groups. … Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in

  7. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  8. Drug

    AMGN-0007

    go.drugbank.com/drugs/DB06511
    Experimental

    Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.

  9. Drug

    MP4

    go.drugbank.com/drugs/DB05313
    Investigational

    MP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. … It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.

  10. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.